WINTER PARK, Fla., Dec. 22, 2020 /PRNewswire/ -- Cytocom, Inc.,
a leading biopharmaceutical company creating second generation
immune therapies, announced today that the company is participating
in Biotech Showcase Digital and H.C. Wainwright BioConnect.
Both events will be held virtually and are scheduled alongside the
J.P. Morgan 39th Annual Healthcare Conference 2021.
Details of the events are as follows:
Event:
|
|
Biotech Showcase
Digital
|
Date:
|
|
January 11-15,
2021
|
Registration:
|
|
https://informaconnect.com/biotech-showcase/registration-options/
|
|
|
|
Event:
|
|
H.C. Wainwright
BioConnect 2021 Conference
|
Date:
|
|
January 11-14,
2021
|
Registration:
|
|
https://hcwevents.com/bioconnect/#
|
During both events, members of the Cytocom management team will
participate in virtual one-on-one meetings with registered
investors and pharmaceutical companies to discuss Cytocom's
business and highlight recent corporate achievements, as well as
anticipated near-term milestones.
Cytocom's two lead investigative compounds, CYTO-201 for the
treatment of Crohn's disease and CYTO-401 for the treatment of
pancreatic cancer, are expected to enter Phase 3 clinical trials in
2021. In July 2020, Cytocom
announced an agreement to acquire ImQuest Life Sciences, Inc.,
a drug development company and contract research organization.
The company followed in October with a definitive merger agreement
with Cleveland Biolabs, Inc. (Nasdaq: CBLI) and plans for a
subsequent listing on Nasdaq Capital Market.
About Cytocom
Cytocom, Inc. is a clinical-stage biopharmaceutical company
developing novel immunotherapies targeting autoimmune,
inflammatory, infectious diseases, and cancers based on a
proprietary platform designed to rebalance the body's immune system
and restore homeostasis. Cytocom is developing therapies designed
to elicit directly within patients a robust and durable response of
antigen-specific killer T cells and antibodies, thereby activating
essential immune defenses against autoimmune, inflammatory,
infectious diseases, and cancers. Specifically, Cytocom has four
programs in late-stage clinical development in Crohn's disease,
fibromyalgia, multiple sclerosis and pancreatic cancer. Cytocom
believes that its technologies can meaningfully leverage the human
immune system for prophylactic and therapeutic purposes by
eliciting killer T cell response levels not achieved by other
published immunotherapy approaches. Cytocom's immunomodulatory
technology restores the balance between the cellular (Th1) and the
humoral (Th2) immune systems. Immune balance is regulated through
T-helper cells that produce cytokines. The Th1 lymphocytes help
fight pathogens within cells like cancer and viruses through
interferon-gamma and macrophages. The Th2 lymphocytes target
external pathogens like cytotoxic parasites, allergens, toxins
through the activation of B-cells and antibody production to effect
to dendritic cells, which are natural activators of killer T cells,
also known as cytotoxic T cells, or CD8+ T cells. Furthermore, the
Cytocom technology antagonizes the toll-like receptors to inhibit
pro-inflammatory cytokines. To learn more about Cytocom, Inc.,
please visit www.cytocom.com.
Forward-Looking Statements:
This release contains forward-looking statements that involve
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things,
uncertainties inherent in research and development; the
uncertainties inherent in business and financial planning,
including, without limitation, risks related to
Cytocom's business and prospects, adverse developments
in Cytocom's markets, or adverse developments in the U.S. or global
capital markets, credit markets, regulatory environment or
economies generally; the impact of COVID-19 on our business,
operations and financial results; and competitive
developments. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of
new information or future events or developments.
Contact
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA/Miriam Miller (Investors)
(212) 375-2664 / 2694
mmcenroe@tiberend.com
mmiller@tiberend.com
Johanna Bennett (Media)
(212) 375-2686
jbennett@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytocom-to-participate-in-biotech-showcase-and-hc-wainwright-bioconnect-2021-during-jp-morgan-week-2021-301197264.html
SOURCE Cytocom, Inc.